Rubicon Research Ltd Q2 FY27 Earnings Call: Guides 24%+ FY27 EBITDA Margin, PAT Jumps 67% YoY

Rubicon Research Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based 40% Growth; PAT Up 67% YoY

• Q2 FY 2026-2027 revenue of Rs.577 crore — up 40% YoY from Rs.412 crore in Q2 FY 2025-2026 and up sequentially from Rs.534 crore in Q1 FY 2026-2027; sequential USD growth resumed at 5% after tactical measures paused growth in Q1 FY 2026-2027.
• Operating EBITDA of Rs.144 crore, up ~53% YoY — EBITDA including other income at Rs.146 crore vs Rs.95 crore YoY; pre-R&D EBITDA at Rs.206 crore with margin expanding to 35.8% from 34.1% YoY.
• PAT of Rs.90 crore vs Rs.54 crore YoY — Q2 EPS at Rs.5.41 vs Rs.3.47 in Q1 FY 2026-2027; Q1 PAT of Rs.85 crore included a one-time insurance claim of Rs.3.6 crore.
• H1 FY 2026-2027 revenue of Rs.1,111 crore (+45% YoY) — operating EBITDA up 57.5% YoY at Rs.273 crore; PAT up 80% YoY at Rs.175 crore.
• Arena consolidation inflates FY27 numbers — Arena revenue of Rs.19.4 crore is included in the quarter, while its EBITDA contribution is not material in both quarters.
• Since listing, quarterly EBITDA has more than doubled — from Rs.72.6 crore to Rs.146.4 crore, which management highlighted as evidence of a consistent quarterly execution track record.

Third Consecutive Quarter of Margin Expansion; FY27 Guidance Raised

• Q2 FY 2026-2027 operating EBITDA margin at 25% — up vs Q1 FY 2026-2027; full-year FY 2026-2027 operating EBITDA guidance raised to 24%+ from 23%+ guided at Q1 FY 2026-2027, which had itself been raised from the earlier 22-23%.
• Third consecutive quarter of gross and EBITDA margin expansion — CEO Parag Sancheti attributed it to products, including legacy products, gaining market share and overall portfolio design, not solely low-margin product rationalization.
• CFO Nitin Jajodia cited specialty share of gross margin and operating leverage — expansion was achieved after factoring in costs associated with the geopolitical situation; some factors impacted positively, others negatively.
• Specialty contribution to gross profit at 36% in Q2 FY 2026-2027 — underpinned by specialty and differentiated products; pricing stable, with top 5/top 10 product revenues range-bound across the last 4 sequential quarters.
• Tactical revenue measures more or less complete — per Parag Sancheti, a few may be completed over the next one or two quarters (Q3–Q4 FY 2026-2027).

Rising Productivity Ratios; Rs.500 Cr Spend Program on Track

• R&D productivity improving across cycles — FY21→FY24 delivered 3.3x (Rs.540 crore incremental product sales on Rs.165 crore reference spend); FY22→FY25 at 4.1x; FY23→FY26 at 5.9x on Rs.226 crore reference spend.
• FY24→FY27 cycle shows 5.8x on the slide — but this uses an FY27 revenue figure of Rs.2,105 crore, an arithmetic annualization of H1 FY 2026-2027 revenue excluding Arena; management expects the ratio to increase as revenue comes through in the remaining two quarters of FY 2026-2027.
• Base-year reconciliation — the slide's FY24 base of Rs.839 crore is lower than the ~Rs.854 crore audited FY24 revenue because it covers product sales only (excluding the service element) and regulated market revenue and R&D only, excluding Arena.
• Rs.500 crore of R&D spend guided for the period spanning FY26, FY27 and Q1 FY28 — Rs.313 crore already incurred over 6 quarters, with good visibility on completing the balance over the remaining 3 quarters.
• Forward reference spend already committed — Rs.275 crore for the FY25→FY28 cycle and Rs.384 crore for the FY26→FY29 cycle (the latter slightly less than double the current cycle's base) has already been completed.
• Management stated visibility on revenue growth for FY29, FY30 and beyond is "pretty strong" — the Rs.500 crore R&D spend is expected, at its productivity rate, to drive incremental revenues to FY30 off the FY27 revenue base.
• Portfolio shifting toward complexity, no hero products — per slide 13, the mix has moved from immediate release tablets (2021) toward drug-device combinations and sizably large individual opportunities closer to FY26–FY27; top 5/top 10 products remain within a narrow band.

Inspection Cadence Intact; India Licensing Change Defers Some Launches

• 3 approvals received in Q2 FY 2026-2027 — commercialization rate strong at 84%.
• India's licensing process has been revised — an export license for controlled as well as other products can now be applied for only after FDA approval is received (previously licenses and manufactured product were pre-positioned for immediate shipment upon approval); as a result of this regulation change, some approvals will be launched in Q3 FY 2026-2027.
• Ambarnath unannounced inspection (October 2026): 3 + 2 observations — all procedural, none related to data integrity; management is confident of working with the regulator to close these successfully and in a timely manner.
• Satara unannounced inspection (October 2026): 1 procedural observation — response already submitted to the agency, EIR awaited.
• Pithampur inspected July 2026 (Q2 FY 2026-2027): 2 observations — already disclosed to the stock exchanges; response submitted the same month; company expects the EIR.
• Clean records elsewhere — the FDA inspected the New Jersey facility in May 2026 (just before the acquisition) with EIR already in place; the Canada R&D site was inspected earlier in FY 2026-2027 with no observations and EIR in place; all four manufacturing sites inspected within the last six months.

~Rs.400 Cr Deployed in Pre-Revenue Sites; Arena Profitability Deliberately Unguided

• ~Rs.400 crore (slightly over 25% of capital employed) in pre-revenue assets — the Pithampur facility (expected to be operationalized soon), the upcoming Chhatrapati Sambhajinagar (Aurangabad) facility, the New Jersey facility, and Arena Life Sciences; ROACE held at 36% as of 30 September 2026, in line with March 2026.
• All 4 sites at zero to very low utilization — Pithampur, CSN, New Jersey and Arena are not contributing meaningfully to the bottom line; pre-operative expenses are routed through the P&L, and the sites add to capital employed while returns are yet to kick in meaningfully.
• Indore facility revenue contribution guided to begin from FY28 onwards — stated by Sagar Oak; for CSN, CEO Parag Sancheti is not putting an exact timeline on revenue contribution, and for New Jersey, revenue will begin only after completing filings, adding products, and clearing FDA inspection — no exact date given.
• Arena in a growth-lever phase — CFO Nitin Jajodia said investment is focused on getting growth back on track, with the next phase being beating IPM growth; profitability focus is "some time away" — no timeline or medium-to-long-term margin guidance provided.
• Sagar Oak declined to guide on Arena margins — preference is to "do" rather than guide, with focus first on revenue and then margins; it is early days for that business.

Working Capital Improved; Strong Visibility Into FY29-FY30

• Net working capital at 117 days as of 30 September 2026 — improved from 126 days; management attributed the improvement to quarterly fluctuation and expects normalization to 125-130 days (period unspecified).
• H1 FY 2026-2027 net operating cash inflow of Rs.99 crore — investing outflow of Rs.172 crore driven by the Arena Life Science acquisition, the New Jersey facility acquisition, and capex; the New Jersey facility added Rs.85 crore to fixed assets (Rs.29 crore cash payout, Rs.55 crore non-cash right-of-use).
• Q2 FY 2026-2027 cash flow strong at nearly Rs.99 crore — per management commentary on the quarter.
• Sequential CC growth of 5% in Q2 FY 2026-2027 — per CEO Parag Sancheti, with management seeing strong visibility in coming quarters.
• Operating leverage expected once sites are commissioned — utilization pickup at Pithampur, CSN and New Jersey is the trigger for returns to materialize on the ~Rs.400 crore deployed.